Resolutions from the Annual General Meeting of Novo Nordisk A/S
21 März 2024 - 3:59PM
Resolutions from the Annual General Meeting of Novo Nordisk A/S
Bagsværd, Denmark, 21 March 2024 - Today, Novo
Nordisk A/S held its Annual General Meeting.
At the Annual General Meeting, Helge Lund, chair of the Board of
Directors communicated: “We are very pleased with the performance
in 2023 which was an exceptional year of innovation, growth, value
creation and impact for Novo Nordisk. Globally, we reached more
than 40 million patients, more patients than at any point in our
100-year history. As we strive to keep pace with demand, we have
invested heavily in our production capacity with the aim of serving
millions more patients worldwide.”
Resolutions adopted at the Annual General
MeetingFinancial year 2023 and
remuneration
- Approval of the Company’s statutory
Annual Report 2023 and distribution of profits according to the
statutory Annual Report 2023.
- The final dividend for 2023 of DKK
6.40 for each Novo Nordisk A and B share of DKK 0.10. The total
dividend for 2023 of DKK 9.40 includes both the interim dividend of
DKK 3.00 for each Novo Nordisk A and B share of DKK 0.10 which was
paid in August 2023 and the final dividend of DKK 6.40 for each
Novo Nordisk A and B share of DKK 0.10 to be paid in March
2024
- Approval of the Remuneration Report
2023 (advisory vote), of the remuneration of the Board of Directors
for 2024, of an indemnification scheme for the Board of Directors
and the Executive Management and of changes to the Remuneration
Policy.
Elections
- Re-election of Helge Lund as chair
of the Board of Directors.
- Re-election of Henrik Poulsen as
vice chair of the Board of Directors.
- Re-election of Laurence Debroux,
Andreas Fibig, Sylvie Grégoire, Christina Law, Kasim Kutay and
Martin Mackay as members of the Board of Directors.
- Appointment of Deloitte
Statsautoriseret Revisionspartnerselskab as the Company’s auditor
in respect of statutory financial and sustainability
reporting.
Shares and capital
- Reduction of the Company’s B share
capital by cancellation of part of the Company’s own holding of B
shares. The Company’s B share capital is reduced by DKK 4,500,000
from DKK 343,512,800 to DKK 339,012,800. The Company’s A share
capital of DKK 107,487,200 remains unchanged, whereby the Company’s
share capital will amount to DKK 339,012,800.
- Authorisation to the Board of
Directors until the Annual General Meeting 2025 to allow the
Company to repurchase own shares of up to 10% of the share capital
subject to a holding limit of 10% of the share capital.
- Extension of the authorisation to the Board of Directors to
increase the Company's share capital for a period of one year until
25 March 2026 up to nominally DKK 44,650,000.
The meeting was held as a hybrid meeting enabling shareholders
to participate either in person or virtually. The shareholders had
been encouraged to exercise their rights by submitting proxies or
votes by correspondence in advance of the Annual General
Meeting.
Composition of the Board of Directors and its
committeesAfter the Annual General Meeting, the Board of
Directors held a board meeting to appoint members of its
committees.
The Board of Directors, including its committees, is now
composed as follows:
- Helge Lund (chair of the Board and
chair of the People and Governance Committee)
- Henrik Poulsen (vice chair of the
Board, chair of the Remuneration Committee and member of the Audit
Committee)
- Elisabeth Dahl Christensen
(employee representative and member of the Remuneration
Committee)
- Laurence Debroux (chair of the
Audit Committee and member of the Remuneration Committee)
- Andreas Fibig (member of the
Research & Development Committee)
- Sylvie Grégoire (member of the
Audit Committee, the People and Governance Committee and the
Research & Development Committee)
- Liselotte Hyveled (employee
representative and member of the Research & Development
Committee)
- Mette Bøjer Jensen (employee
representative and member of the Audit Committee)
- Kasim Kutay (member of the People
and Governance Committee and the Research & Development
Committee)
- Christina Law (member of the Audit
Committee)
- Martin Mackay (chair of the
Research & Development Committee and member of the Remuneration
Committee)
- Thomas Rantzau (employee
representative and member of the People and Governance
Committee)
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat serious chronic diseases, built upon our heritage in
diabetes. We do so by pioneering scientific breakthroughs,
expanding access to our medicines, and working to prevent and
ultimately cure disease. Novo Nordisk employs about 63,400 people
in 80 countries and markets its products in around 170 countries.
Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more
information, visit novonordisk.com, Facebook, Instagram, X,
LinkedIn and YouTube.
Contacts for further information
Media: |
|
Ambre
James-Brown +45 3079 9289abmo@novonordisk.com |
Liz
Skrbkova (US)+1 609 917 0632lzsk@novonordisk.com |
Investors: |
|
Daniel
Muusmann Bohsen+45 3075 2175 dabo@novonordisk.com |
Jacob
Martin Wiborg Rode+45 3075 5956jrde@novonordisk.com |
David
Heiberg Landsted +45 3077 6915 dhel@novonordisk.com |
Mark
Joseph Root (US) +1 848 213 3219mjhr@novonordisk.com |
Sina
Meyer +45 3079 6656azey@novonordisk.com |
Frederik
Taylor Pitter +45 3075 8259fptr@novonordisk.com |
Company announcement No 24 / 2024
- CA240321_Resolutions from the AGM
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Mai 2023 bis Mai 2024